SI3134095T1 - Izboljšani postopki za izdelavo adoptivnih celičnih terapij - Google Patents

Izboljšani postopki za izdelavo adoptivnih celičnih terapij

Info

Publication number
SI3134095T1
SI3134095T1 SI201531225T SI201531225T SI3134095T1 SI 3134095 T1 SI3134095 T1 SI 3134095T1 SI 201531225 T SI201531225 T SI 201531225T SI 201531225 T SI201531225 T SI 201531225T SI 3134095 T1 SI3134095 T1 SI 3134095T1
Authority
SI
Slovenia
Prior art keywords
improved methods
adoptive cell
cell therapies
manufacturing
manufacturing adoptive
Prior art date
Application number
SI201531225T
Other languages
English (en)
Inventor
Richard Morgan
Kevin Friedman
Dawn Maier
Original Assignee
Bluebird Bio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54333268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3134095(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bluebird Bio, Inc. filed Critical Bluebird Bio, Inc.
Publication of SI3134095T1 publication Critical patent/SI3134095T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
SI201531225T 2014-04-25 2015-04-24 Izboljšani postopki za izdelavo adoptivnih celičnih terapij SI3134095T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461984558P 2014-04-25 2014-04-25
PCT/US2015/027518 WO2015164745A1 (en) 2014-04-25 2015-04-24 Improved methods for manufacturing adoptive cell therapies
EP15783117.3A EP3134095B1 (en) 2014-04-25 2015-04-24 Improved methods for manufacturing adoptive cell therapies

Publications (1)

Publication Number Publication Date
SI3134095T1 true SI3134095T1 (sl) 2020-08-31

Family

ID=54333268

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531225T SI3134095T1 (sl) 2014-04-25 2015-04-24 Izboljšani postopki za izdelavo adoptivnih celičnih terapij

Country Status (25)

Country Link
US (1) US20170051252A1 (sl)
EP (2) EP3738597A1 (sl)
JP (4) JP6817069B2 (sl)
KR (3) KR20160141865A (sl)
CN (2) CN106456670B (sl)
AU (2) AU2015249376C1 (sl)
BR (1) BR112016024957A2 (sl)
CA (1) CA2946552A1 (sl)
CY (1) CY1123142T1 (sl)
DK (1) DK3134095T3 (sl)
ES (1) ES2800906T3 (sl)
HR (1) HRP20200978T1 (sl)
HU (1) HUE049514T2 (sl)
IL (2) IL248349B (sl)
LT (1) LT3134095T (sl)
MX (2) MX370018B (sl)
NZ (1) NZ725201A (sl)
PL (1) PL3134095T3 (sl)
PT (1) PT3134095T (sl)
RS (1) RS60544B1 (sl)
RU (1) RU2741899C2 (sl)
SG (2) SG10201808258SA (sl)
SI (1) SI3134095T1 (sl)
WO (1) WO2015164745A1 (sl)
ZA (2) ZA201607175B (sl)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113512522A (zh) 2013-03-15 2021-10-19 普林斯顿大学理事会 用于高通量纯化的方法和设备
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
CN105264127B (zh) 2013-03-15 2019-04-09 Gpb科学有限责任公司 颗粒的片上微流体处理
EP3132247B1 (en) 2014-04-16 2021-08-18 Juno Therapeutics GmbH Methods, kits and apparatus for expanding a population of cells
SG11201608862SA (en) 2014-04-23 2016-11-29 Juno Therapeutics Inc Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
DK3689899T3 (da) 2014-04-25 2021-11-22 2Seventy Bio Inc Kimære mnd-promotor-antigenreceptorer
CN111394317A (zh) 2014-06-06 2020-07-10 蓝鸟生物公司 改善的t细胞组合物
MX2017001079A (es) * 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
EA036379B1 (ru) 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CA3197849A1 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP4234685A3 (en) 2015-04-17 2023-09-06 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
FR3038324B1 (fr) 2015-06-30 2020-10-30 Lab Francais Du Fractionnement Procede de cryoconservation de cellules a visee therapeutique
TW201708538A (zh) 2015-07-21 2017-03-01 諾華公司 改良免疫細胞之功效及擴展之方法
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
TWI630934B (zh) * 2015-10-14 2018-08-01 瑞典商神經毫微股份有限公司 移植醫藥設備到神經組織中的方法以及設備
CA3002742A1 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
EA201891066A1 (ru) 2015-10-30 2018-10-31 ЭнБиИ-ТЕРАПЬЮТИКС АГ Антитела к ror1
WO2017099712A1 (en) * 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
CA3009852A1 (en) * 2015-12-28 2017-07-06 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
TW201736399A (zh) 2015-12-31 2017-10-16 財團法人生物技術開發中心 抗vegfr抗體及其應用
MX2018008926A (es) 2016-01-20 2019-01-10 Scripps Research Inst Composiciones de anticuerpo contra ror1 y métodos relacionados.
WO2017177137A1 (en) * 2016-04-07 2017-10-12 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions
CN108778312B (zh) * 2016-04-08 2022-07-15 爱默蕾大学 使用基于细胞的疗法治疗癌症和传染病的方法
CN105907790A (zh) * 2016-06-21 2016-08-31 林志国 特异性识别EGFRvⅢ的含CD70嵌合抗原受体修饰T细胞的制备方法
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
PL3445787T3 (pl) 2016-10-07 2021-05-31 TCR2 Therapeutics Inc. Kompozycje i sposoby reprogramowania receptorów limfocytów t przy użyciu białek fuzyjnych
WO2018075940A1 (en) * 2016-10-21 2018-04-26 Georgia Tech Research Corporation Methods and systems for t cell expansion
AU2017350739B2 (en) * 2016-10-24 2023-03-16 Gpb Scientific, Inc. Deterministic lateral displacement in the preparation of cells and compositions for therapeutic uses
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2018136566A1 (en) * 2017-01-18 2018-07-26 F1 Oncology, Inc. Methods of transducing and expanding immune cells and uses thereof
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
CN110832075A (zh) 2017-03-22 2020-02-21 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
CN110678190A (zh) * 2017-03-28 2020-01-10 宾夕法尼亚大学董事会 保护移植的组织免受排斥的方法
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN109134660B (zh) * 2017-06-16 2022-07-01 上海恒润达生生物科技股份有限公司 靶向Mesothelin的嵌合抗原受体并联合表达抗PD1抗体的方法及其用途
CN107236762A (zh) * 2017-06-19 2017-10-10 河北浓孚雨生物科技有限公司 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法
JP2020525470A (ja) * 2017-07-03 2020-08-27 ディヴェロップメント センター フォー バイオテクノロジー 抗ｖｅｇｆｒ抗体及びその使用
CN111133002A (zh) 2017-08-07 2020-05-08 恩比伊治疗股份公司 具有高体内耐受性的基于蒽环类药的抗体药物缀合物
MX2020001490A (es) 2017-08-09 2020-08-06 Juno Therapeutics Inc Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas.
AU2018323875A1 (en) 2017-09-01 2020-04-23 Gpb Scientific, Inc. Methods for preparing therapeutically active cells using microfluidics
CN115216450A (zh) * 2017-09-01 2022-10-21 隆萨沃克斯维尔股份有限公司 端到端细胞治疗自动化
KR20200086278A (ko) 2017-10-18 2020-07-16 노파르티스 아게 선택적 단백질 분해를 위한 조성물 및 방법
CN107893055B (zh) * 2017-11-03 2020-07-17 深圳市默赛尔生物医学科技发展有限公司 一种特异性嵌合抗原受体基因修饰的自然杀伤细胞及其制备方法和用途
WO2019094835A1 (en) * 2017-11-10 2019-05-16 Juno Therapeutics, Inc. Closed-system cryogenic vessels
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
TW201922774A (zh) 2017-11-15 2019-06-16 瑞士商諾華公司 標靶bcma嵌合抗原受體、標靶cd19嵌合抗原受體及組合療法
KR20200096253A (ko) 2017-11-30 2020-08-11 노파르티스 아게 Bcma-표적화 키메라 항원 수용체, 및 이의 용도
JP2021505168A (ja) * 2017-12-08 2021-02-18 ジュノー セラピューティクス インコーポレイテッド 操作されたｔ細胞の組成物を製造するための方法
CN109609533B (zh) * 2017-12-27 2020-07-10 赛德特生物科技开发有限公司 基于人源化cd276抗体的car慢病毒表达载体构建及其应用
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
CN108239144B (zh) * 2018-01-26 2021-05-25 重庆精准生物技术有限公司 改造的铰链及其在构建car骨架中的应用
CA3090249A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
DE102018108996B4 (de) 2018-02-09 2021-10-21 Immatics US, Inc. Verfahren zur Herstellung autologer T-Zellen
KR20200119840A (ko) * 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019178314A1 (en) * 2018-03-14 2019-09-19 Thermogenesis Corporation Buoyancy-activated cell sorting (bacs)-compatible activation/transduction systems and methods
CN110272481A (zh) * 2018-03-14 2019-09-24 中国科学院广州生物医药与健康研究院 识别mage1抗原短肽的t细胞受体
DE102018108612A1 (de) * 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
MX2020011134A (es) * 2018-04-27 2020-11-11 Iovance Biotherapeutics Inc Proceso cerrado para expansion y edicion de genes de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia.
CN112424342A (zh) * 2018-05-08 2021-02-26 生命科技公司 用于培养和扩增细胞的组合物和方法
CN108929862A (zh) * 2018-08-01 2018-12-04 上海市第人民医院 一种恶性肿瘤肺转移伴恶性胸腔积液的t细胞制备与扩增方法及其应用
AU2019331496A1 (en) 2018-08-31 2021-03-18 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
MX2021005372A (es) 2018-11-08 2021-09-14 Neximmune Inc Composiciones de linfocitos t con propiedades fenotípicas mejoradas.
PT3880802T (pt) * 2018-11-16 2022-12-16 Celgene Corp Processo melhorado de fabrico de células t
CN113286813A (zh) * 2018-11-19 2021-08-20 得克萨斯大学体系董事会 用于car和tcr转导的模块化多顺反子载体
CN113366099A (zh) 2018-12-21 2021-09-07 奥克泰生物科技股份有限公司 用于模块化生物生产单元的转盘
JP2022514761A (ja) 2018-12-21 2022-02-15 ロンザ ウォーカーズヴィル，インコーポレーテッド ウイルスベクターの自動産生方法
SG11202108473XA (en) 2019-02-08 2021-09-29 Lonza Walkersville Inc Cell concentration methods and devices for use in automated bioreactors
EP3930763A1 (en) 2019-02-25 2022-01-05 Novartis AG Mesoporous silica particles compositions for viral delivery
US20200297768A1 (en) * 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
AU2020256246A1 (en) * 2019-04-03 2021-11-04 Akron Biotechnology, Llc Cryopreservation and cell culture media
WO2020206061A1 (en) * 2019-04-05 2020-10-08 Bluebird Bio, Inc. Manufacturing anti-bcma car t cells
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
EP4021180A4 (en) * 2019-08-29 2023-11-08 Board of Regents, The University of Texas System CELL CRYOPRESERVATION MEDIUM
US20210093669A1 (en) * 2019-09-26 2021-04-01 Nantbio, Inc. Primary T-Cell Expansion
CN110747166B (zh) * 2019-10-11 2021-07-09 厦门大学 一种外周血t细胞的体外扩增培养方法
CN114761037A (zh) 2019-11-26 2022-07-15 诺华股份有限公司 结合bcma和cd19的嵌合抗原受体及其用途
KR20220146530A (ko) * 2020-02-27 2022-11-01 노파르티스 아게 키메라 항원 수용체-발현 세포의 제조 방법
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
CA3176356A1 (en) * 2020-04-22 2021-10-28 Anne BROOKS Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
IL300489A (en) 2020-08-21 2023-04-01 Novartis Ag Compositions and methods for in vivo production of CAR expressing cells
JP2024515793A (ja) 2021-04-27 2024-04-10 ノバルティス アーゲー ウイルスベクター生産システム
AR126838A1 (es) * 2021-08-20 2023-11-22 Novartis Ag Métodos para preparar células que expresan receptores de antígeno quiméricos
CN114317435B (zh) * 2021-12-30 2024-02-27 杭州芯递力生物科技有限公司 一种获得抗原特异性t细胞的方法
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
AU726198B2 (en) * 1996-03-04 2000-11-02 Targeted Genetics Corporation Modified rapid expansion methods ("modified-REM") for in vitro propagation of T lymphocytes
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
ES2302726T3 (es) * 2000-02-24 2008-08-01 Invitrogen Corporation Estimulacion y concentracion simultanea de celulas.
US7745592B2 (en) 2001-05-01 2010-06-29 National Research Council Of Canada Cumate-inducible expression system for eukaryotic cells
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
CA2525519A1 (en) * 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
US20080311095A1 (en) * 2007-05-23 2008-12-18 Sangamo Biosciences, Inc. Methods and compositions for increased transgene expression
ES2653570T3 (es) * 2004-05-27 2018-02-07 The Trustees Of The University Of Pennsylvania Células presentadoras de antígeno artificiales novedosas y usos de las mismas
US20080274091A1 (en) 2005-05-20 2008-11-06 Virxsys Corporation Autologous T Cell Manufacturing Processes
ES2911246T3 (es) 2009-11-03 2022-05-18 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas
DK3214091T3 (en) 2010-12-09 2019-01-07 Univ Pennsylvania USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
US9476028B2 (en) * 2011-04-13 2016-10-25 Immunicum Ab Method for proliferation of antigen-specific T cells
EA201491572A1 (ru) * 2012-02-22 2014-12-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции и способы получения устойчивой популяции t-клеток, используемых для лечения злокачественного новообразования
CA2869562C (en) 2012-04-11 2023-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
BR112015004522A2 (pt) * 2012-09-04 2017-11-21 Cellectis receptor de antígeno quimérico multicadeia e usos destes
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
HUE050797T2 (hu) * 2012-10-10 2021-01-28 Sangamo Therapeutics Inc T-sejt módosító vegyületek és alkalmazásaik
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies

Also Published As

Publication number Publication date
HUE049514T2 (hu) 2020-09-28
BR112016024957A2 (pt) 2017-10-24
SG11201608744VA (en) 2016-11-29
CA2946552A1 (en) 2015-10-29
HRP20200978T1 (hr) 2020-10-16
IL276593A (en) 2020-09-30
ES2800906T3 (es) 2021-01-05
KR102161927B1 (ko) 2020-10-06
AU2018203687C1 (en) 2022-01-13
AU2015249376B2 (en) 2018-03-08
JP2017513891A (ja) 2017-06-01
IL248349A0 (en) 2016-11-30
JP7012056B2 (ja) 2022-02-10
JP2020015767A (ja) 2020-01-30
JP2018087254A (ja) 2018-06-07
AU2015249376A1 (en) 2016-11-03
CN106456670B (zh) 2020-01-07
IL276593B (en) 2021-10-31
MX2016013963A (es) 2017-06-12
EP3134095A1 (en) 2017-03-01
LT3134095T (lt) 2020-06-10
ZA201902286B (en) 2022-08-31
EP3738597A1 (en) 2020-11-18
CY1123142T1 (el) 2021-10-29
PL3134095T3 (pl) 2020-10-19
ZA201607175B (en) 2022-08-31
DK3134095T3 (da) 2020-06-29
AU2018203687A1 (en) 2018-06-21
MX370018B (es) 2019-11-28
EP3134095A4 (en) 2017-09-20
JP2022040287A (ja) 2022-03-10
KR20190066089A (ko) 2019-06-12
IL248349B (en) 2020-08-31
KR101988614B1 (ko) 2019-06-12
KR20160141865A (ko) 2016-12-09
EP3134095B1 (en) 2020-04-22
KR20180105733A (ko) 2018-09-28
MX2019014009A (es) 2020-02-05
RU2016145968A (ru) 2018-05-28
NZ725201A (en) 2018-05-25
CN106456670A (zh) 2017-02-22
AU2015249376C1 (en) 2019-10-31
US20170051252A1 (en) 2017-02-23
CN110819595A (zh) 2020-02-21
PT3134095T (pt) 2020-07-02
AU2018203687B2 (en) 2019-03-21
WO2015164745A1 (en) 2015-10-29
RU2741899C2 (ru) 2021-01-29
SG10201808258SA (en) 2018-10-30
JP6817069B2 (ja) 2021-01-20
RU2016145968A3 (sl) 2018-11-13
RS60544B1 (sr) 2020-08-31

Similar Documents

Publication Publication Date Title
IL276593B (en) Improved methods for producing adoptive cell therapies
IL274903A (en) cell
HK1244826A1 (zh) 用於過繼細胞治療的方法和組合物
IL250072A0 (en) Transgenic cells for stress cell therapy
SG11201703493SA (en) Cell culture insert
EP3036639A4 (en) STORAGE CLUSTER
SG11201701369VA (en) Separator for battery
HK1248555A1 (zh) 基因修飾的t細胞的選擇方法
EP3233097A4 (en) Improved cell therapies
HUE042287T2 (hu) Lítium-kén cella
GB201413781D0 (en) Fuel cell
GB201411625D0 (en) Fuel cell
SG10201403640XA (en) Stem cells
IL248910A0 (en) Cell culture tray
AU2014905156A0 (en) Improved cell therapies
GB201413395D0 (en) Cell separation methods
GB201421342D0 (en) Cell culture
GB201410934D0 (en) T cell
GB201420088D0 (en) Battery modules and methods for their manufacture
AU362174S (en) Battery pack
GB201416750D0 (en) Cell preparation
GB201401068D0 (en) Cell maturation process